Effects of adjuvants on IgG subclasses elicited by virus-like Particles

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Visciano, Maria Luisa ^a   Tagliamonte, Maria ^a   Tornesello, Maria Lina ^a   Buonaguro, Franco M ^a   Buonaguro, Luigi ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; IMMUNOLOGICAL ADJUVANT; POLYINOSINIC POLYCYTIDYLIC ACID; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; GAG PROTEIN; GP140 ENVELOPE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; OLIGODEOXYRIBONUCLEOTIDE; VIRUS ENVELOPE PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOREACTIVITY; LYMPHOCYTE DIFFERENTIATION; MALE; MOUSE; NONHUMAN; POLARIZATION; PROVOCATION TEST; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; VIRUS LIKE AGENT; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL POLARITY; CLASSIFICATION; CYTOLOGY; DRUG EFFECT; FEMALE; IMMUNIZATION; IMMUNOLOGY; KINETICS; VIRION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY SPECIFICITY; CELL POLARITY; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; HIV ANTIBODIES; HIV ANTIGENS; HIV CORE PROTEIN P24; HIV-1; IMMUNITY, HUMORAL; IMMUNIZATION; IMMUNOGLOBULIN G; KINETICS; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; POLY I-C; TH1 CELLS; TH2 CELLS; VIRION;

EID: 84855396893     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-4     Document Type: Article

References (92)

1. Ross AL, Brave A, Scarlatti G, Manrique A, Buonaguro L. Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. Lancet Infect Dis 2010, 10:305-316. 10.1016/S1473-3099(10)70069-4, 20417413.
2. Buonaguro L, Tornesello ML, Buonaguro FM. Virus-Like Particles as Particulate Vaccines. Curr HIV Res 2010, 8:299-399. 10.2174/157016210791208659, 20353398.
3. Bachmann MF, Lutz MB, Layton GT, Harris SJ, Fehr T, Rescigno M, Ricciardi-Castagnoli P. Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Eur J Immunol 1996, 26:2595-2600. 10.1002/eji.1830261109, 8921944.
4. Ruedl C, Storni T, Lechner F, Bachi T, Bachmann MF. Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur J Immunol 2002, 32:818-825. 10.1002/1521-4141(200203)32:3<818::AID-IMMU818>3.0.CO;2-U, 11870626.
5. Buonaguro FM, Tornesello ML, Buonaguro L. Virus-like particle vaccines and adjuvants: the HPV paradigm. Expert Rev Vaccines 2009, 8:1379-1398. 10.1586/erv.09.81, 19803760.
6. Andre FE, Safary A. Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine. Postgrad Med J 1987, 63(Suppl 2):169-177.
7. Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines 2009, 8:1663-1679. 10.1586/erv.09.123, 19943762.
8. Harper DM. Preliminary HPV vaccine results for women older than 25 years. Lancet 2009, 373:1921-1922. 10.1016/S0140-6736(09)61045-X, 19501728.
9. Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods 2006, 40:60-65. 10.1016/j.ymeth.2006.07.018, 16997714.
10. Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, Kumar NM, Pushko P, Smith G, Tumpey TM, Ross TM. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008, 3:e1501. 10.1371/journal.pone.0001501, 2200794, 18231588.
11. Deml L, Speth C, Dierich MP, Wolf H, Wagner R. Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol 2005, 42:259-277. 10.1016/j.molimm.2004.06.028, 15488613.
12. Young KR, McBurney SP, Karkhanis LU, Ross TM. Virus-like particles: designing an effective AIDS vaccine. Methods 2006, 40:98-117. 10.1016/j.ymeth.2006.05.024, 16997718.
13. Buonaguro L, Visciano ML, Tornesello ML, Tagliamonte M, Biryahwaho B, Buonaguro FM. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J Virol 2005, 79:7059-7067. 10.1128/JVI.79.11.7059-7067.2005, 1112107, 15890945.
14. Buonaguro L, Devito C, Tornesello ML, Schroder U, Wahren B, Hinkula J, Buonaguro FM. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 2007, 25:5968-5977. 10.1016/j.vaccine.2007.05.052, 17629365.
15. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci USA 2003, 100:6753-6758. 10.1073/pnas.1131929100, 164519, 12748380.
16. Hammarstrom L, Smith CI. IgG subclasses in bacterial infections. Monogr Allergy 1986, 19:122-133.
17. Linde A, Sundqvist VA, Mathiesen T, Wahren B. IgG subclasses to subviral components. Monogr Allergy 1988, 23:27-32.
18. Ferrante A, Beard LJ, Feldman RG. IgG subclass distribution of antibodies to bacterial and viral antigens. Pediatr Infect Dis J 1990, 9:S16-S24.
19. Powers DC. Effect of age on serum immunoglobulin G subclass antibody responses to inactivated influenza virus vaccine. J Med Virol 1994, 43:57-61. 10.1002/jmv.1890430111, 8083650.
20. Sanders LA, Rijkers GT, Tenbergen-Meekes AM, Voorhorst-Ogink MM, Zegers BJ. Immunoglobulin isotype-specific antibody responses to pneumococcal polysaccharide vaccine in patients with recurrent bacterial respiratory tract infections. Pediatr Res 1995, 37:812-819. 10.1203/00006450-199506000-00023, 7651768.
21. Adderson EE, Shackelford PG, Quinn A, Carroll WL. Restricted Ig H chain V gene usage in the human antibody response to Haemophilus influenzae type b capsular polysaccharide. J Immunol 1991, 147:1667-1674.
22. Adderson EE, Shackelford PG, Quinn A, Wilson PM, Cunningham MW, Insel RA, Carroll WL. Restricted immunoglobulin VH usage and VDJ combinations in the human response to Haemophilus influenzae type b capsular polysaccharide. Nucleotide sequences of monospecific anti-Haemophilus antibodies and polyspecific antibodies cross-reacting with self antigens. J Clin Invest 1993, 91:2734-2743. 10.1172/JCI116514, 443339, 8514881.
23. Siber GR, Schur PH, Aisenberg AC, Weitzman SA, Schiffman G. Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. N Engl J Med 1980, 303:178-182. 10.1056/NEJM198007243030402, 6966763.
24. Bachmann MF, Zinkernagel RM. The influence of virus structure on antibody responses and virus serotype formation. Immunol Today 1996, 17:553-558. 10.1016/S0167-5699(96)10066-9, 8991286.
25. Schumaker VN, Calcott MA, Spiegelberg HL, Muller-Eberhard HJ. Ultracentifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement. Biochemistry 1976, 15:5175-5181. 10.1021/bi00668a035, 990273.
26. Anderson CL, Loone RJ. Human leukocyte IgG Fc receptors. Immunology Today 1986, 7(9):264-266. Ref Type: Journal (Full).
27. Snapper CM, Finkelman FD. Immunoglobulin class switching. Fundamental Immunology 1999, 831. Philadelphia: Lippincott-Raven, Paul WE.
28. Banerjee K, Klasse PJ, Sanders RW, Pereyra F, Michael E, Lu M, Walker BD, Moore JP. IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res Hum Retroviruses 2010, 26:445-458. 10.1089/aid.2009.0223, 2864049, 20377426.
29. Ngo-Giang-Huong N, Candotti D, Goubar A, Autran B, Maynart M, Sicard D, Clauvel JP, Agut H, Costagliola D, Rouzioux C. HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. AIDS Res Hum Retroviruses 2001, 17:1435-1446. 10.1089/088922201753197105, 11679156.
30. Sundqvist VA, Linde A, Kurth R, Werner A, Helm EB, Popovic M, Gallo RC, Wahren B. Restricted IgG subclass responses to HTLV-III/LAV and to cytomegalovirus in patients with AIDS and lymphadenopathy syndrome. J Infect Dis 1986, 153:970-973. 10.1093/infdis/153.5.970, 3009638.
31. Gorse GJ, Patel GB, Mandava M, Berman PW, Belshe RB. MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group. AIDS Res Hum Retroviruses 1999, 15:921-930. 10.1089/088922299310638, 10408729.
32. Jankovic D, Caspar P, Zweig M, Garcia-Moll M, Showalter SD, Vogel FR, Sher A. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. J Immunol 1997, 159:2409-2417.
33. Visciano ML, Tuen M, Gorny MK, Hioe CE. In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120. Virology 2008, 372:409-420. 10.1016/j.virol.2007.10.044, 2288784, 18054978.
34. Banerjee K, Andjelic S, Klasse PJ, Kang Y, Sanders RW, Michael E, Durso RJ, Ketas TJ, Olson WC, Moore JP. Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. Virology 2009, 389:108-121. 10.1016/j.virol.2009.04.001, 2743082, 19410272.
35. Chin'ombe N, Bourn WR, Williamson AL, Shephard EG. Oral vaccination with a recombinant Salmonella vaccine vector provokes systemic HIV-1 subtype C Gag-specific CD4+ Th1 and Th2 cell immune responses in mice. Virol J 2009, 6:87. 10.1186/1743-422X-6-87, 2708135, 19555490.
36. Bielinska AU, Janczak KW, Landers JJ, Markovitz DM, Montefiori DC, Baker JR. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res Hum Retroviruses 2008, 24:271-281. 10.1089/aid.2007.0148, 18260780.
37. Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol 2005, 174:7676-7683.
38. Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 1998, 160:870-876.
39. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745. 10.1038/35047123, 11130078.
40. Baker PJ, Hiernaux JR, Fauntleroy MB, Stashak PW, Prescott B, Cantrell JL, Rudbach JA. Ability of monophosphoryl lipid A to augment the antibody response of young mice. Infect Immun 1988, 56:3064-3066. 259701, 2972626.
41. Weeratna RD, Brazolot Millan CL, McCluskie MJ, Davis HL. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol Med Microbiol 2001, 32:65-71. 10.1111/j.1574-695X.2001.tb00535.x, 11750224.
42. Stahl-Hennig C, Eisenblatter M, Jasny E, Rzehak T, Tenner-Racz K, Trumpfheller C, Salazar AM, Uberla K, Nieto K, Kleinschmidt J, Schulte R, Gissmann L, Muller M, Sacher A, Racz P, Steinman RM, Uguccioni M, Ignatius R. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog 2009, 5:e1000373. 10.1371/journal.ppat.1000373, 2660151, 19360120.
43. Wuorimaa T, Dagan R, Vakevainen M, Bailleux F, Haikala R, Yaich M, Eskola J, Kayhty H. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J Infect Dis 2001, 184:1211-1215. 10.1086/323648, 11598848.
44. Lefeber DJ, aissa-Trouw B, Vliegenthart JF, Kamerling JP, Jansen WT, Kraaijeveld K, Snippe H. Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3. Infect Immun 2003, 71:6915-6920. 10.1128/IAI.71.12.6915-6920.2003, 308892, 14638780.
45. Buonaguro L, Del Gaudio E, Monaco M, Greco D, Corti P, Beth-Giraldo E, Buonaguro FM, Giraldo G. Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of HIV 1 isolates from Gulu-Northern Uganda. J Virol 1995, 69:7971-7981. 189742, 7494310.
46. Buonaguro L, Buonaguro FM, Russo F, Tornesello ML, Beth-Giraldo E, Wagner R, Wolf H, Giraldo G. A novel gp120 sequence from an HIV-1 isolate of the A clade identified in North Uganda. AIDS Res Hum Retroviruses 1998, 14:1287-1289. 10.1089/aid.1998.14.1287, 9764913.
47. Buonaguro L, Buonaguro FM, Tornesello ML, Mantas D, Beth-Giraldo E, Wagner R, Michelson S, Prevost M-C, Wolf H, Giraldo G. High efficient production of Pr55gag Virus-like Particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Research 2001, 49:35-47. 10.1016/S0166-3542(00)00136-4, 11166859.
48. Tagliamonte M, Visciano ML, Tornesello ML, De SA, Buonaguro FM, Buonaguro L. HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line. Vaccine 2011,
49. Buonaguro L, Racioppi L, Tornesello ML, Arra C, Visciano ML, Biryahwaho B, Sempala SDK, Giraldo G, Buonaguro FM. Induction of neutralizing antibodies and CTLs in Balb/c mice immunized with Virus-like Particles presenting a gp120 molecule from a HIV-1 isolate of clade A (HIV-VLPAs). Antiviral Research 2002, 54:189-201. 10.1016/S0166-3542(02)00004-9, 12062391.
50. Visciano ML, Diomede L, Tagliamonte M, Tornesello ML, Asti V, Bomsel M, Buonaguro FM, Lopalco L, Buonaguro L. Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins. Vaccine 2011,
51. Aricò E, Wang E, Tornesello ML, Tagliamonte M, Lewis GK, Marincola FM, Buonaguro FM, Buonaguro L. Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation. J Transl Med 2005, 3:45. 10.1186/1479-5876-3-45, 1360684, 16384534.
52. Buonaguro L, Monaco A, Arico E, Wang E, Tornesello ML, Lewis GK, Marincola FM, Buonaguro FM. Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. BMC Bioinformatics 2008, 9(Suppl 2):S5. 10.1186/1471-2105-9-S2-S5, 2323668, 18387207.
53. Buonaguro L, Tornesello ML, Gallo RC, Marincola FM, Lewis GK, Buonaguro FM. Th2 Polarization in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus (HIV)-Infected Subjects, as Activated by HIV Virus-Like Particles. J Virol 2009, 83:304-313. 10.1128/JVI.01606-08, 2612330, 18945779.
54. Buonaguro L, Tornesello ML, Jewis GK, Buonaguro FM. Short communication: limited induction of IL-10 in PBMCs from HIV-infected subjects treated with HIV-VLPs. AIDS Res Hum Retroviruses 2009, 25:819-822. 10.1089/aid.2008.0304, 2858928, 19630502.
55. Klinman DM, Currie D, Gursel I, Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 2004, 199:201-216. 10.1111/j.0105-2896.2004.00148.x, 15233736.
56. Klinman DM. Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol 2006, 25:135-154. 10.1080/08830180600743057, 16818369.
57. Jin B, Sun T, Yu XH, Liu CQ, Yang YX, Lu P, Fu SF, Qiu HB, Yeo AE. Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant. J Biomed Biotechnol 2010, 2010:690438. 2910503, 20671921.
58. Meylan E, Tschopp J. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol Cell 2006, 22:561-569. 10.1016/j.molcel.2006.05.012, 16762830.
59. Matsumoto M, Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev 2008, 60:805-812. 10.1016/j.addr.2007.11.005, 18262679.
60. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, Salazar AM, Colonna M, Steinman RM. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 2009, 206:1589-1602. 10.1084/jem.20090247, 2715098, 19564349.
61. Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, Kalinke U, Tough DF. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 2006, 176:2074-2078.
62. Tewari K, Flynn BJ, Boscardin SB, Kastenmueller K, Salazar AM, Anderson CA, Soundarapandian V, Ahumada A, Keler T, Hoffman SL, Nussenzweig MC, Steinman RM, Seder RA. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CSP in non human primates. Vaccine 2010, 28:7256-7266. 10.1016/j.vaccine.2010.08.098, 3004225, 20846528.
63. Le BA, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, Borrow P, Tough DF. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 2003, 4:1009-1015.
64. Le BA, Durand V, Kamphuis E, Thompson C, Bulfone-Paus S, Rossmann C, Kalinke U, Tough DF. Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J Immunol 2006, 176:4682-4689.
65. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:546-549. 10.1038/374546a0, 7700380.
66. Verthelyi D, Zeuner RA. Differential signaling by CpG DNA in DCs and B cells: not just TLR9. Trends Immunol 2003, 24:519-522. 10.1016/S1471-4906(03)00243-6, 14552833.
67. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 1996, 93:2879-2883. 10.1073/pnas.93.7.2879, 39727, 8610135.
68. Sun S, Zhang X, Tough DF, Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 1998, 188:2335-2342. 10.1084/jem.188.12.2335, 2212431, 9858519.
69. Stacey KJ, Sweet MJ, Hume DA. Macrophages ingest and are activated by bacterial DNA. J Immunol 1996, 157:2116-2122.
70. Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996, 157:1840-1845.
71. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, Kornbluth RS, Richman DD, Carson DA, Raz E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997, 3:849-854. 10.1038/nm0897-849, 9256274.
72. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 1996, 93:2879-2883. 10.1073/pnas.93.7.2879, 39727, 8610135.
73. Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996, 157:1840-1845.
74. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, Kornbluth RS, Richman DD, Carson DA, Raz E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997, 3:849-854. 10.1038/nm0897-849, 9256274.
75. Halpern MD, Kurlander RJ, Pisetsky DS. Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell Immunol 1996, 167:72-78. 10.1006/cimm.1996.0009, 8548847.
76. Gupta RK, Siber GR. Adjuvants for human vaccines--current status, problems and future prospects. Vaccine 1995, 13:1263-1276. 10.1016/0264-410X(95)00011-O, 8585280.
77. Krieg AM. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta 1999, 1489:107-116.
78. McCluskie MJ, Davis HL. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 1998, 161:4463-4466.
79. Visciano ML, Diomede L, Tagliamonte M, Tornesello ML, Asti V, Bomsel M, Buonaguro FM, Lopalco L, Buonaguro L. Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins. Vaccine 2011,
80. Rovinski B, Haynes JR, Cao SX, James O, Sia C, Zolla-Pazner S, Matthews TJ, Klein MH. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross- protective AIDS vaccine. J Virol 1992, 66:4003-4012. 241203, 1602531.
81. Tagliamonte M, Visciano ML, Tornesello ML, De SA, Buonaguro FM, Buonaguro L. HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line. Vaccine 2011, 29:4913-4922. 10.1016/j.vaccine.2011.05.004, 21596085.
82. McIntyre TM, Klinman DR, Rothman P, Lugo M, Dasch JR, Mond JJ, Snapper CM. Transforming growth factor beta 1 selectivity stimulates immunoglobulin G2b secretion by lipopolysaccharide-activated murine B cells. J Exp Med 1993, 177:1031-1037. 10.1084/jem.177.4.1031, 2190989, 8459202.
83. Weiner HL. Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect 2001, 3:947-954. 10.1016/S1286-4579(01)01456-3, 11564443.
84. Martinez V, Costagliola D, Bonduelle O, N'go N, Schnuriger A, Theodorou I, Clauvel JP, Sicard D, Agut H, Debre P, Rouzioux C, Autran B. Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis 2005, 191:2053-2063. 10.1086/430320, 15897991.
85. Le BA, Schiavoni G, D''Agostino G, Gresser I, Belardelli F, Tough DF. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001, 14:461-470. 10.1016/S1074-7613(01)00126-1, 11336691.
86. Swanson CL, Wilson TJ, Strauch P, Colonna M, Pelanda R, Torres RM. Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response. J Exp Med 2010, 207:1485-1500. 10.1084/jem.20092695, 2901065, 20566717.
87. Scharf O, Golding H, King LR, Eller N, Frazier D, Golding B, Scott DE. Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1. J Virol 2001, 75:6558-6565. 10.1128/JVI.75.14.6558-6565.2001, 114379, 11413323.
88. Gray ES, Madiga MC, Moore PL, Mlisana K, bdool Karim SS, Binley JM, Shaw GM, Mascola JR, Morris L. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol 2009, 83:11265-11274. 10.1128/JVI.01359-09, 2772769, 19692477.
89. Pejchal R, Walker LM, Stanfield RL, Phogat SK, Koff WC, Poignard P, Burton DR, Wilson IA. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci USA 2010, 107:11483-11488. 10.1073/pnas.1004600107, 2895122, 20534513.
90. Saphire EO, Parren PW, Barbas CF, Burton DR, Wilson IA. Crystallization and preliminary structure determination of an intact human immunoglobulin, b12: an antibody that broadly neutralizes primary isolates of HIV-1. Acta Crystallogr D Biol Crystallogr 2001, 57:168-171. 10.1107/S0907444900017376, 11134947.
91. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW, Rudd PM, Dwek RA, Katinger H, Burton DR, Wilson IA. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003, 300:2065-2071. 10.1126/science.1083182, 12829775.
92. Vogel FR. Improving vaccine performance with adjuvants. Clin Infect Dis 2000, 30(Suppl 3):S266-S270.